About Kritika Sarmah
Her interest in risky instruments and passion for writing made Kritika an analyst and financial journalist.
She earned her bachelor's degree in commerce and is currently pursuing the CFA program.
With her fundamental approach, she aims to help investors identify untapped investment opportunities.
Recent Articles By Kritika Sarmah
Strategies for Capitalizing on Advanced Micro Devices (AMD) Earnings Momentum
Despite an impressive first quarter earnings report, shares of Advanced Micro Devices (AMD) are in a downward spiral. Let's delve into the intricacies of AMD's current market dynamics to uncover the underlying reasons behind this unexpected turn of events...
Buy Alert: 3 Pharma Stocks Under $20 to Invest in Now
With rising medicine demand and drug shortages in the U.S., pharmaceutical stocks under $20 present lucrative opportunities for investors, promising substantial returns in a ripe market. So, I think fundamentally solid pharma stocks ACADIA Pharmaceuticals (ACAD), Amneal Pharmaceuticals (AMRX), and OptiNose (OPTN), which are currently trading under $20, could be ideal investments now. Keep reading...
Amazon (AMZN) Post-Earnings Reflection: Buy, Hold, or Sell?
Amazon (AMZN) just dropped its first quarter earnings bombshell, smashing revenue and EPS expectations and cementing its reign as a retail titan. But should you ride the wave? Let's unravel the mystery...
Coca-Cola (KO) Earnings Analysis: Is Now the Time to Buy?
Coca-Cola (KO) just announced its first-quarter results, defying expectations with solid earnings. However, let us examine its performance, segment dynamics, and financial outlook to determine whether now is the opportune moment to buy into this beverage titan...
4 Biotech Stocks to Watch Closely in May
With soaring drug demand and the recent inauguration of the National Bioeconomy Board, the biotech sector in the U.S. stands as an attractive investment opportunity. So, fundamentally strong biotech stocks Akebia Therapeutics (AKBA), Organogenesis Holdings (ORGO), Alnylam Pharmaceuticals (ALNY), and G1 Therapeutics (GTHX) might be ideal additions to one’s watchlist in May. Read more...
Mastercard (MA) Earnings Forecast: Worth a Closer Look?
Payment power Mastercard (MA) is set to announce its first-quarter earnings result on May 1st. As investors eagerly await this financial update, let us analyze the company's recent performance and strategic initiatives to gauge its potential...
Exxon Mobil (XOM) Earnings Analysis: Ideal Time to Buy?
While the energy sector demonstrated resilience last year, falling natural gas prices could pose challenges this year. Industry leader Exxon Mobil (XOM) recently released its earnings, which paints an unclear picture. Let's analyze and find out if now could be an ideal time to buy the stock. Read on to find out...
GOOGL Earnings Breakdown and Optimizing Your Portfolio Strategy
With Alphabet's (GOOGL) earnings drawing near, investors eagerly await the potential earnings from its key services like Google Search, YouTube ad revenue, and Google Cloud. Join us as we delve into GOOGL's performance, offering insights to fine-tune your portfolio strategy...
Will MSFT Add Value to Your Watchlist During Earnings?
As Microsoft (MSFT) gears up to announce its earnings on April 25, investors are eagerly awaiting to see if the tech giant will continue to impress. Despite its robust emphasis on cloud services and strategic AI investments, MSFT's recent downturns in personal and gaming revenues have sparked concerns. Is MSFT poised to enhance your watchlist with its upcoming earnings report? Let's explore...